Stay updated on Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:26:58.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of the Phase 2 clinical trial evaluating the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:56.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying requirements such as age, health status, and prior treatments. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    37%
    Check dated 2024-05-22T21:12:22.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:18:12.000Z thumbnail image

Stay in the know with updates to Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab in Platinum-Sensitive Gynecologic Cancer Clinical Trial page.